SAM
TGTX icon

Shell Asset Management’s TG Therapeutics TGTX Stock Holding History

Shell Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,314
Closed -$37K – 1403
2022
Q3 		$37K Sell
6,314
-813
-11% -$5.33K ﹤0.01% 1350
2022
Q2 		$30K Buy
7,127
+154
+2% +$962 ﹤0.01% 1384
2022
Q1 		$66K Sell
6,973
-1,024
-13% -$11.9K ﹤0.01% 1332
2021
Q4 		$152K Buy
7,997
+193
+2% +$5.01K ﹤0.01% 1270
2021
Q3 		$260K Sell
7,804
-330
-4% -$10.2K 0.01% 1123
2021
Q2 		$316K Sell
8,134
-6,211
-43% -$244K 0.01% 1102
2021
Q1 		$691K Buy
14,345
+4,739
+49% +$228K 0.01% 700
2020
Q4 		$500K Buy
+9,606
New +$325K 0.01% 802

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Shell Asset Management's TGTX Position: Q4 2022 in Review

Shell Asset Management sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 6,314 shares — an estimated $37K sold.

Shell Asset Management first reported a position in TGTX in Q4 2020 and held it in 8 quarters. The position peaked at $691K in Q1 2021. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

  • Shell Asset Management reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Shell Asset Management sold 6,314 TG Therapeutics shares in Q4 2022, an estimated $37K.
  • Shell Asset Management first reported a position in TG Therapeutics in Q4 2020 and held it in 8 quarters.
  • Shell Asset Management's TG Therapeutics position peaked at $691K in Q1 2021.
  • 198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Shell Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.